Q-omics provides the consensus-scored GJE1 profile across patient tissues and cancer cell-line models. GJE1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GJE1 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, GJE1 RNA expression shows 5,953 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, and STAD as cancer lineages where GJE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJE1 survival associations across molecular data types. GJE1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJE1 RNA expression–survival associations across cancer types. High GJE1 expression shows unfavorable associations in BLCA, ACC, UVM and OV, but favorable associations in ESCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GJE1 RNA expression.
This table summarizes GJE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for GJE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJE1 shows higher tumor expression in STAD. The STAD box plot shows higher GJE1 RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .045).
This table shows molecular features associated with GJE1 in patient tissues and cancer cell lines. In patient samples, GJE1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GJE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OVARY.
